Free and open to the public.
Daniel Finley is Professor of Cell Biology at Harvard Medical School. Finley’s research has focused on understanding how the proteasome recognizes its substrates, how it coordinates deubquitination with protein degradation, how it assembles, and how it unfolds and translocates the substrate in preparation for degradation. His research, in collaboration with Dr. Randall King, has led to the discovery of a novel target, Usp14, which inhibits proteasome activity by decoupling ubiquitin tags from proteins, as well as small molecule inhibitors of Usp14 that increase turnover of neurotoxic or damaged proteins. Finley is a scientific co-founder of Proteostasis Therapeutics, which seeks to develop groundbreaking therapies to treat diseases caused by dysfunctional protein processing.